Renamed newcomer will be positioned between the Sonet and Seltos and go on-sale in early 2025 in India with South African market availability unknown at present.

That’s right. Kia has teased the upcoming crossover called the Syros. For now, the Korean manufacturer intends to offer it in ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.

Find out the latest Kia Syros car price, reviews, specifications, images, mileage, videos and more. Get expert reviews on the ...

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after ...

Fintel reports that on November 13, 2024, JMP Securities downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) ...

Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

The interiors similarly would be different and would be similar to the EV9 with a clean minimalistic look while it would be ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...